🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB

    Novartis Pharmaceuticals

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 small molecule active

    1 trial

  2. FNP-223, Film coated tabled

    Ferrer Internacional S.A.

    Progressive supranuclear palsy (PSP)

    phase 2 small molecule active

    1 trial

  3. FOLFOX/FOLFIRI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  4. FOLFOXIRI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Cancer

    phase 2 small molecule active

    1 trial

  5. FOLFOXIRI-based HAIC+Fuquinitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Neoplasms

    phase 2 small molecule completed

    1 trial

  6. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, S241656 film-coated tablet 50mg, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion, S241656 film-coated tablet 25mg, Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung,

    The George Institute

    Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

    phase 2 small molecule active

    1 trial

  7. FORTRANS, poudre pour solution buvable en sachet., TOXICARB, suspension buvable

    Pari Pharma GmbH

    Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.

    phase 2 small molecule active

    1 trial

  8. FST-100 Ophthalmic Suspension

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule terminated

    1 trial

  9. Famitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule on hold

    1 trial

  10. Faropenem

    Hospital Authority, Hong Kong

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  11. Fasedienol Nasal Spray - Placebo Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 2 small molecule active

    1 trial

  12. Faslodex 250 mg solution for injection., PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB

    Ningbo Cancer Hospital

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  13. Favipiravir

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Influenza, Human

    phase 2 small molecule completed

    1 trial

  14. Fecal microbiota transplantation (FMT)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Slow Transit Constipation

    phase 2 small molecule active

    1 trial

  15. Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion

    Biogen

    Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants

    phase 2 small molecule active

    1 trial

  16. Ficerafusp alfa

    Bicara Therapeutics

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  17. Ficerafusp alfa

    Bicara Therapeutics

    Squamous Cell Carcinoma of Head and Neck (SCCHN)

    phase 2 small molecule active

    1 trial

  18. Film-coated placebo to match estetrol monohydrate (E4) 20mg tablet

    Estetra SPRL

    postmenopausal women with vasomotor menopausal symptoms

    phase 2 small molecule active

    1 trial

  19. First-line Cohort

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  20. Fludarabina Accord 25 mg/ml concentrado para solución inyectable y para perfusión., HSP-CAR30, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión

    The George Institute

    Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma

    phase 2 small molecule active

    1 trial

  21. Fludarabine (FLU)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Aplastic Anemia Idiopathic

    phase 2 small molecule active

    1 trial

  22. Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB

    Iovance Biotherapeutics B.V.

    Metastatic Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. Fluoxetine

    The First People's Hospital of Lianyungang

    Depression

    phase 2 small molecule active

    1 trial

  24. Fluoxetine (drug)

    The First People's Hospital of Lianyungang

    Hepatobiliary Malignancy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources